Product Information
MEROPENEM IV 1 GM VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $4.6875 per EA under NDC 00143943110. Its NADAC has been published 87 times since Feb 5, 2025.
FDA first approved this application on Jul 22, 2024. Its Orange Book therapeutic-equivalence code is AP.
Strength
1 g/30mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00143943110
Classification
Generic
Dosage Form
INJECTION
Route
INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
MEROPENEMApproval Type
Generic (ANDA)
FDA Application
ANDA216424FDA Approved
7/22/2024
TE Code
AP
On Market Since
9/1/2024
Pharmacological Classes
Price Statistics
The NADAC for MEROPENEM IV 1 GM VIAL has been published 87 times since Feb 5, 2025, and over the history we have for it it has declined 24.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.6875 per EA |
|---|---|
| All-time high | $6.2356 (Feb 12, 2025) |
| All-time low | $4.6687 (Aug 19, 2026) |
| 52-week high | $5.8381 |
| 52-week low | $4.6687 |
| Median price | $5.5712 |
| Average price | $5.4659 |
| Largest weekly change | -7.5% (Feb 19, 2025) |
| Weeks tracked | 87 |
| Tracking since | Feb 5, 2025 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Meropenem market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Penem Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEROPENEM IV 1 GM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for MEROPENEM IV 1 GM VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $4.6875 per EA (NDC 00143943110), effective Sep 30, 2026.
How has the price of MEROPENEM IV 1 GM VIAL changed over time?
Over the history we have for it, the NADAC for MEROPENEM IV 1 GM VIAL has declined 24.8%. It has been tracked across 87 weekly CMS publications since Feb 5, 2025.
What are the highest and lowest recorded NADAC prices for MEROPENEM IV 1 GM VIAL?
Since Feb 5, 2025, the NADAC for MEROPENEM IV 1 GM VIAL has ranged from a low of $4.6687 (Aug 19, 2026) to a high of $6.2356 (Feb 12, 2025), with a median of $5.5712 per EA.
Are there cheaper alternatives to MEROPENEM IV 1 GM VIAL?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MEROPENEM IV 1 GM VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures MEROPENEM IV 1 GM VIAL?
MEROPENEM IV 1 GM VIAL (NDC 00143943110) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.